Advances in stroke: Translational medicine 2012

Stroke

Volumn 44, Issue 2, 2013, Pages 318-319

  Planas, Anna M ^a  

^a INST D INVESTIGACIONS B   (Spain)

Author keywords

acute stroke; clinical; experimental; translation; treatment

Indexed keywords

GLUCOSE TRANSPORTER 2; MAGNESIUM SULFATE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN INHIBITOR; TAT NR2B9C; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; URIC ACID;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; ENDOVASCULAR ANEURYSM REPAIR; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; STEM CELL TRANSPLANTATION; SUBARACHNOID HEMORRHAGE; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; PEPTIDES; STEM CELL TRANSPLANTATION; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84872917238     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000495     Document Type: Article

References (26)

1. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD- 95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483: 213-217.
2. Tymianski M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci. 2011;14:1369-1373.
3. Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al; ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942-950.
4. van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain. 2007;130(pt 12):3063-3074.
5. van der Worp HB, Macleod MR, Kollmar R; European Stroke Research Network for Hypothermia (EuroHYP). Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab. 2010;30:1079-1093.
6. Amaro S, Chamorro Á. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke. 2011;42:1495-1499.
7. Saver JL. Time is brain-quantified. Stroke. 2006;37:263-266.
8. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 2004;3:744-751.
9. Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401-410.
10. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69:576-581.
11. Dirnagl U. Pathobiology of injury after stroke: the neurovascular unit and beyond. Ann N Y Acad Sci. 2012;1268:21-25.
12. Komotar RJ, Starke RM, Arias EJ, Garrett MC, Otten ML, Merkow MB, et al. The complement cascade: new avenues in stroke therapy. Curr Vasc Pharmacol. 2009;7:287-292.
13. Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, Torres F, et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS ONE. 2010;5:e8433.
14. Orsini F, Villa P, Parrella S, Zangari R, Zanier ER, Gesuete R, et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation. 2012;126:1484-1494.
15. Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA. 2007;104:14104-14109.
16. Liu J, Jin X, Liu KJ, Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J Neurosci. 2012;32:3044-3057.
17. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42:3323-3328.
18. Prabhakaran S, Naidech AM. Ischemic brain injury after intracerebral hemorrhage: a critical review. Stroke. 2012;43:2258-2263.
19. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11:720-731.
20. Caner B, Hou J, Altay O, Fuj M 2nd, Zhang JH. Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J Neurochem. 2012;123(suppl 2):12-21.
21. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders- time for clinical translation? J Clin Invest. 2010;120:29-40.
22. Smith HK, Gavins FN. The potential of stem cell therapy for stroke: is PISCES the sign? FASEB J. 2012;26:2239-2252.
23. Oki K, Tatarishvili J, Wood J, Koch P, Wattananit S, Mine Y, et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells. 2012;30:1120-1133.
24. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009;10:861-872.
25. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol. 2012;11:369-380.
26. Yanev P, Dijkhuizen RM. In vivo imaging of neurovascular remodeling after stroke. Stroke. 2012;43:3436-3441.